Hutch News
Results per Page:
Six researchers receive $3.5 million in grants from Kuni Foundation
Funds will support innovative high-risk/high-reward projects across Fred Hutchinson Cancer Center/University of Washington/Seattle Children’s Cancer Consortium with the potential to revolutionize care
Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow
Rare skin cancer is focus of work by Fred Hutch scientist who will receive support honoring runner Gabe Grunewald
Enhance, enhance! Computational tool “BayesSpace” zooms in to fine-map spatial transcriptomics
From the Gottardo, Bielas, and Nghiem Labs, Biostatistics and Computational Biology Program, Cancer Consortium
$12M NIH grant to study rare, aggressive skin cancer
Fred Hutch, UW researchers hope to improve immunotherapies for people with Merkel cell carcinoma
Pembrolizumab treatment for Merkel cell carcinoma
From the Nghiem Laboratory, Clinical Research Division
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma
Seattle team pivotal to FDA OK on drug for rare skin cancer
UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
Revealing a new way that cancer can evade immunotherapy — and, maybe, how to stop it
How a new technology solved a mystery and honors one man’s legacy
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
Immunotherapy has long-term benefit for patients with advanced Merkel cell carcinoma
‘Incredibly big change’ in treatment of deadly skin cancer, new data show
10 highlights of Fred Hutch science in 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more
Galloway receives NCI Outstanding Investigator Award
Leader in HPV research will work to improve detection, prevention and treatment of virally caused cancers
Triple therapy for rare skin cancer shows promise in small, early-stage trial
Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer
Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma
Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer
Benefit seen in nearly one-third of patients ‘with no hope at all of surviving’ their treatment-resistant Merkel cell carcinoma
Immunotherapy trial in rare skin cancer named one of 2016’s major advances in clinical cancer research and care
Study found long-lasting responses to immunotherapy drug in patients with Merkel cell carcinoma